Form 4: Bristol-Myers Squibb Director Acquires Deferred Share Units

Director Derica W. Rice acquired 3,562.431 deferred share units of Bristol-Myers Squibb on February 1, 2025, convertible to common stock upon ceasing to be a director or at a previously specified future date.

Summary

• On February 1, 2025, Derica W. Rice, a director of Bristol-Myers Squibb, acquired 3,562.431 deferred share units.
• These units will convert into shares of common stock upon settlement.
• Settlement occurs when Rice ceases to be a director or at a future date he previously specified.
• The price per share for the deferred share units is $58.95.
• Following the transaction, Rice beneficially owns 30,681.172 deferred share units, which includes deferred compensation and reinvested dividends.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing, indicating a neutral sentiment. It simply reports a transaction.

Future Outlook

The deferred share units will be converted into common stock upon settlement, which will occur when the reporting person ceases to be a director or at a future date previously specified.

Industry Context

This filing is a routine disclosure of a director's transaction in company stock, which is common in publicly traded companies. It provides transparency to investors regarding the holdings and transactions of company insiders.

Stakeholder Impact

• The transaction provides transparency to shareholders regarding the director's holdings.

Key Dates

Keywords

Form 4, Beneficial Ownership, Deferred Share Units, Director, Bristol-Myers Squibb, BMY, Rice, Derica W. Rice